INTRODUCTION {#s1}
============

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most deadly malignancies with frequent metastasis and recurrence \[[@R1]\]. Most cases with pancreatic cancer are diagnosed in advanced stages and are ineligible for potentially curative resection, which lead to a poor prognosis with a 5-year survival rate of 6% in all patients \[[@R2]\]. Although great endeavors have been made in early diagnosis, surgical resection and systemic chemotherapy for pancreatic cancer, the poor outcome of pancreatic cancer has remained unchanged since 40 years \[[@R3]\]. The disappointing survival rates for pancreatic cancer indicate the aggressive nature of this deadly disease. Therefore, to overcome this global challenging problem, a thorough understanding of the molecular mechanisms underlying the progression of pancreatic cancer is urgently needed \[[@R4], [@R5]\].

Extracellular matrix (ECM) proteins are made up of secreted molecules with implications in developmental patterning, stem cell niches and cancer \[[@R6]\]. Epidermal Growth Factor-like repeats and Discoidin I-Like Domains 3 (EDIL3), also known as developmentally regulated endothelial cell locus 1 (DEL-1), is a secreted (ECM) protein that composed of three epidermal growth factor (EGF) domains and two discoidin I-Like repeats \[[@R7]\]. EDIL3 is involved in the regulation of angiogenesis, cell attachment, and migration through an Arg-Gly-Asp (RGD) motif in its second EGF repeats by interacting with α~v~β~3~ integrin \[[@R7]--[@R9]\]. EDIL3 is an embryonic endothelial cell protein and is not expressed after birth \[[@R7]\]. However, it has been demonstrated that EDIL3 was expressed in multiple types of cancer including breast cancer \[[@R10], [@R11]\], colon cancer \[[@R12]\], bladder cancer \[[@R13]\] and hepatocellular carcinoma \[[@R14]--[@R16]\]. Overexpressed EDIL3 can reduce tumor cell apoptosis and increase tumor vascularization, thus promoting tumor growth \[[@R10]\]. The capabilities of EDIL3 in tumor vascularization make it a candidate target for cancer anti-angiogenic therapy and also other diseases characterized by abnormal vascularization \[[@R17], [@R18]\]. In colon cancer, down-regulation of EDIL3 inhibits tumor growth by anti-angiogenesis and anti-proliferation \[[@R12]\]. In hepatocellular carcinoma, elevated autocrine EDIL3 protects cancer cells from anoikis through RGD-mediated integrin activation \[[@R15]\]. However, little is known about the expression pattern and cellular functions of EDIL3 in pancreatic cancer.

Anoikis is a specific form of apoptosis that occurs when cells detached from inappropriate ECM \[[@R19]\]. Acquisition of anoikis resistance is a critical process of metastasis by favoring cancer cells to survive during invasion and transference to the blood and lymph. Numerous potential regulators involved in anoikis of PDAC cells have been proposed, such as integrins and the anti-apoptotic Bcl-2 family members \[[@R20]\]. EDIL3 is a well known ligand for α~v~β~3~ integrin and activation of α~v~β~3~ integrin can induce the expression of Bcl-2 in endothelial cell \[[@R21]\].

In the present study, we performed investigations to determine (a) the expression pattern and clinical significance of EDIL3 in pancreatic cancer, (b) the underlying roles of EDIL3 in pancreatic cancer cells, and (c) possible mechanism involved in EDIL3-mediated functions.

RESULTS {#s2}
=======

EDIL3 mRNA and protein are significantly up-regulated in PDAC {#s2_1}
-------------------------------------------------------------

To illustrate the expression pattern of EDIL3 in PDAC, we firstly searched the mRNA expression level of EDIL3 in three GEO datasets. The results showed that EDIL3 expression was significantly up-regulated in PDAC tissues comparing with paired normal pancreatic tissues using GSE15471 (Figure [1A](#F1){ref-type="fig"}, *n* = 39, *p* = 1.33E-11) and GSE28735 (Figure [1B](#F1){ref-type="fig"}, *n* = 45, *p* = 3.73E-8). Expression of EDIL3 was also remarkably higher in the PDAC tissues than the normal pancreas as revealed by GSE16515 (Figure [1C](#F1){ref-type="fig"}, *p* = 0.0008). In present study, similar result was also observed in 32 paired PDAC and non-cancerous tissues as demonstrated by quantitative real-time PCR (Figure [1D](#F1){ref-type="fig"}, *n* = 32, *p* = 0.0004). To further address the protein change of EDIL3 in PDAC tissues, Immunohistochemical analysis was performed in two independent PDAC tissue microarrays (TMA). In the commercial TMA (TMA1, OD-CT-DgPan01-006), we found that EDIL3 was significantly up-regulated in chronic pancreatitis (CHP) tissues and PDAC tissues compared with normal pancreas (NP) (Figure [1F](#F1){ref-type="fig"}). Importantly, EDIL3 immunoreactivity was specially distributed in PDAC cells except for islets. The representative staining of EDIL3 expression in NP, CHP as well as PDAC tissues were shown in Figure [1E](#F1){ref-type="fig"} and [1G](#F1){ref-type="fig"}. In TMA2, the expression of EDIL3 protein was also pronounced elevated in PDAC tissues and the pancreatic intraepithelial neoplasia-3 (PanIN3) compared with their normal counterparts (Figure [1H](#F1){ref-type="fig"}, *p* = 7.74E-69).

![EDIL3 expression is increased in pancreatic cancer\
(**A**) The mRNA expression of EDIL3 is upregulated in PDAC tissues (T) compared with the normal pancreas tissues (N) revealed using the GSE15471 dataset. (**B**) EDIL3 expression in the normal pancreas and PDAC tissues revealed by the GSE28735 dataset. (**C**) EDIL3 expression analysis in the normal pancreas and PDAC tissues in the GSE16515 dataset. (**D**) The mRNA expression level of EDIL3 in 32 matched tumor (T) and non-tumor tissue (N) derived from Ren Ji cohort was detected by Real-time quantitative PCR. (**E**) Representative photographs of the EDIL3 immunoreactivity in normal pancreas (NP), chronic pancreatitis (CP) and PDAC tissues in TMA1 (scale bar: 100 μm). (**F**) Comparisons of EDIL3 expression in TMA1 revealed by IHC analysis in NP, CP and PDAC tissues. (**G**) Representative photographs of the EDIL3 staining in NP, pancreatic intraepithelial neoplasia-3 (PanIN3) and PDAC tissues in TMA2. The arrows represent positive staining of EDIL3 in the islets (scale bar: 100 μm). (**H**) Comparisons of EDIL3 expression in TMA2 revealed by IHC analysis in NP, PanIN3 and PDAC tissues.](oncotarget-07-4226-g001){#F1}

Relationship between EDIL3 expression and clinical parameters in patients with PDAC {#s2_2}
-----------------------------------------------------------------------------------

To determine the clinical significance of EDIL3 expression in PDAC, the Chi-square test was used to assess the relationships between EDIL3 protein expression and corresponding patients' clinicopathologic parameters including age, gender, tumor location, TNM stage, tumor size, T classification, lymph node metastasis, distant metastasis, vascular invasion and histological differentiation in TMA2. The results showed that EDIL3 expression in PDAC tissues was significantly correlated with TNM stage (*p* = 0.024) and T classification (*p* = 0.006), while no significant associations were observed between EDIL3 expression and age, gender, tumor location, tumor size lymph node metastasis, distant metastasis, vascular invasion and histological differentiation (Table [1](#T1){ref-type="table"}).

###### Correlations between EDIL3 expression and clinicopathologic parameters in patients with PDAC in TMA2

  Clinicopathological parameter      Total 205   Expression of EDIL3   *p* value    
  ---------------------------------- ----------- --------------------- ------------ -----------
  **Age (years)**                                                                   
   \< 65                             97          24 (24.7)             73 (75.3)    0.911
   ≥ 65                              108         26 (24.1)             82 (75.9)    
  **Gender**                                                                        
   Male                              117         29 (24.8)             88 (75.2)    0.879
   Female                            88          21 (23.9)             67 (76.1)    
  **Tumor location**                                                                
   Head                              139         37 (26.6)             102 (73.4)   0.281
   Body/tail                         66          13 (19.7)             53 (80.3)    
  **TNM (AJCC)**                                                                    
   Stage I                           38          16 (42.1)             22 (57.9)    **0.024**
   Stage II                          132         28 (21.2)             104 (78.8)   
   Stage III                         21          5 (23.8)              16 (76.2)    
   Stage IV                          14          1 (7.1)               13 (92.9)    
  **Tumor size**                                                                    
   ≤ 2 cm                            27          9 (33.3)              18 (66.7)    0.246
   \> 2 cm                           178         41 (23.0)             137 (77.0)   
  **T classification**                                                              
   T1, 2                             42          17 (40.5)             25 (59.5)    **0.006**
   T3, 4                             163         33 (20.2)             130 (79.8)   
  **Lymph node metastasis**                                                         
   Absent                            136         38 (26.6)             98 (73.4)    0.096
   Present                           69          12 (19.4)             57 (80.6)    
  **Distant metastasis**                                                            
   Absent                            191         49 (25.7)             142 (74.3)   0.120
   Present                           14          1 (7.1)               13 (92.9)    
  **Vascular invasion**                                                             
   Absent                            178         45 (25.3)             133 (74.7)   0.446
   Present                           27          5 (18.5)              22 (81.5)    
  **Histological differentiation**                                                  
   Well                              11          4 (36.4)              7 (63.6)     0.468
   Moderate/poor                     194         46 (23.7)             148 (76.3)   

The bold number represents the *p*-values with significant differences. *P* value was calculated by χ^2^ test or Fisher\'s exact test.

Up-regulated EDIL3 predicts poor prognosis of PDAC patients {#s2_3}
-----------------------------------------------------------

To evaluate the prognostic significance of EDIL3 in PDAC patients, the correlation between EDIL3 expression and corresponding clinical follow-up information were analyzed by Kaplan-Meier analysis and log-rank test. We first determined the prognostic value of EDIL3 at mRNA level using GSE28735. Three specimens without follow-up information were excluded from study. As shown in Figure [2A](#F2){ref-type="fig"}, patients with higher EDIL3 level (expression value \> 8) had significantly shorter survival time than those with a lower EDIL3 level (expression value ≤ 8). At protein level, as demonstrated in TMA1, patients with higher EDIL3 expression had markedly decreased survival time than those with lower EDIL3 expression (Figure [2B](#F2){ref-type="fig"}, *p* = 0.0119). To increase the statistic power of this result, we determined the prognostic value of EDIL3 in TMA2 with a total of 163 cases enrolled. And we found that high EDIL3 protein expression was remarkably associated with decreased overall survival (Figure [2C](#F2){ref-type="fig"}, *p* = 0.0036). In addition, we determined the correlation between EDIL3 expression and overall survival in PDAC patients in early or advanced TNM stage and in the presence or absence of lymphatic metastasis. Kaplan-Meier analyses showed that overall survival was shorter in PDAC patients with higher EDIL3 expression regardless the state of TNM stage (Figure [2D](#F2){ref-type="fig"}) and lymphatic metastasis (Figure [2E](#F2){ref-type="fig"}). Furthermore, univariate and multivariate analyses were performed to identify the risk factor correlated with patients' prognosis in TMA2. Univariate Cox regression analyses showed that EDIL3 expression, age, TNM stage, tumor size, lymph node metastasis, distant metastasis and histological differentiation were significantly associated with overall survival (Table [2](#T2){ref-type="table"}). Meanwhile, a multivariate Cox regression analysis identified that EDIL3 expression, age, lymph node metastasis and histological differentiation as independent predictors of the overall survival in patients with PDAC (Table [2](#T2){ref-type="table"}). Taken together, these data above suggest that up-regulated EDIL3 predicts poor prognosis and might contribute to tumor progression in PDAC.

![EDIL3 expression is correlated with overall survival rate independent of TNM stage and lymph node metastasis\
(**A**) The correlation between EDIL3 expression and patient survival was conducted in GSE28735 dataset. (**B**) Overall survival analysis of PDAC patients with different EDIL3 protein expression in TMA1. (**C**) Overall survival analysis of PDAC patients with different EDIL3 protein expression in TMA2. (**D**) Comparison of overall survival in patients with or without lymph node metastasis was conducted based on EDIL3 expression. (**E**) Comparisons of overall survival between lower EDIL3 expression group and higher EDIL3 expression group in early TNM stage (I--II) cohort and in advanced TNM stage (III--IV) cohort. *P* value was calculated by log-rank test.](oncotarget-07-4226-g002){#F2}

###### Univariate and multivariate analysis of prognostic parameters for survival in patients with PDAC in TMA2

  Prognostic parameter HR                                     Univariate analysis   Multivariate analysis                                      
  ----------------------------------------------------------- --------------------- ----------------------- ----------- ------- -------------- -----------
  **Expression of EDIL3** (low vs. high)                      1.893                 1.229--2.916            **0.004**   1.717   1.106--2.663   **0.016**
  **Age** (\< 65 vs. ≥ 65)                                    1.521                 1.077--2.149            **0.017**   1.836   1.270--2.654   **0.001**
  **Gender** (male vs. female)                                0.734                 0.514--1.047            0.088       \-      \-             \-
  **Tumor location** (head vs. body/tail)                     1.019                 0.708--1.466            0.920       \-      \-             \-
  **TNM stage** (I--II vs. III--IV)                           1.267                 1.011--1.588            **0.040**   0.930   0.648--1.334   0.692
  **Tumor size** (≤ 2 cm vs. \> 2 cm)                         2.141                 1.182--3.879            **0.012**   1.773   0.971--3.238   0.062
  **T classification** (T1, 2 vs. T3, 4)                      1.347                 0.869--2.086            0.182       \-      \-             \-
  **Lymph node metastasis** (absent vs. present)              1.487                 1.049--2.109            **0.026**   1.688   1.133--2.515   0.010
  **Distant metastasis** (absent vs. present)                 1.945                 1.041--3.634            **0.037**   2.195   0.844--5.705   0.107
  **Vascular invasion** (absent vs. present)                  1.579                 0.969--2.572            0.067       \-      \-             \-
  **Histological differentiation** (well vs. moderate/poor)   2.475                 1.011--6.058            **0.047**   2.825   1.141          **0.025**

HR: Hazard ratio; CI: Confidence interval. The bold number represents the *p* value with significant differences.

EDIL3 inhibits anoikis and promotes anchorage-independent tumor growth in PDAC cells *in vitro* {#s2_4}
-----------------------------------------------------------------------------------------------

Given the close relationship between EDIL3 expression and poor clinical prognosis, we further determined the biological cellular functions of EDIL3 in PDAC cells. Consistent with the findings in PDAC tissues, EDIL3 expression was remarkably up-regulated in all of six pancreatic cancer cell lines in relative to the nonmalignant hTERT-HPNE cells at both mRNA level (Figure [3A](#F3){ref-type="fig"}), protein level (Figure [3B](#F3){ref-type="fig"}) and secreted level (Figure [3C](#F3){ref-type="fig"}). Two PDAC cell lines with relatively higher EDIL3 expression, SW1990 and BxPC-3 cells, were selected for loss-of-function study. Stable expression of two short hairpin RNA (sh-1, sh-2) targeting EDIL3 resulted in \> 75% decrease in EDIL3 expression of SW1990 and BxPC-3 cells (Figure [3D](#F3){ref-type="fig"}). CCK-8 assay showed that there was no significant difference in cell viability between sh-Ctrl group and sh-EDIL3 group regardless of the presence ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}) and absence ([Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}) of 10% fetal bovine serum. Transwell model was used to analyze the invasive potential. The result showed that knockdown of EDIL3 also failed to affect cell migration ([Supplementary Figure 1C](#SD1){ref-type="supplementary-material"}) or invasion ([Supplementary Figure 1D](#SD1){ref-type="supplementary-material"}) in SW1990 and BxPC-3 cells. Meanwhile, cell apoptosis assay and anoikis assay were performed by flow cytometric analysis. Indeed, cell apoptosis induced by serum deprivation for 48 h was not affected upon silencing of EDIL3 ([Supplementary Figure 1E](#SD1){ref-type="supplementary-material"}), which significantly inhibited anoikis resistance of SW1990 and BxPC-3 cells (Figure [3E](#F3){ref-type="fig"}). Consistent with this, we found caspase-3/7 activity in PDAC cells suspended in poly-Hema coated dishes for 48 h was markedly promoted by silencing of EDIL3 (Figure [3F](#F3){ref-type="fig"}). To further validate the role of EDIL3 in anoikis resistance, colony formation assay was performed. As shown in Figure [3G](#F3){ref-type="fig"}, silencing of EDIL3 significantly reduced the anchorage-independent growth of SW1990 and BxPC-3 cells.

![Knockdown of EDIL3 promotes anoikis and inhibits anchorage-independent tumor growth in PDAC cells\
The mRNA (**A**), protein (**B**), secreted (**C**) levels of EDIL3 were assessed in six pancreatic cancer cell lines as well as a nonmalignant cell line hTERT-HPNE by quantitative real-time PCR, Western blotting and ELISA, respectively. (**D**) Interfere efficacy in SW1990 and BxPC-3 cell was detected by Western blotting. Knockdown of EDIL3 promoted anoikis as revealed by flow cytometry (**E**) and caspase-3/7 activity (**F**), and inhibited the colony formation ability (**G**) of SW1990 and BxPC-3 cells. Scale bar: 5 mm. sh-Ctrl versus sh-1 or sh-2, \**P* \< 0.05, \*\**P* \< 0.01.](oncotarget-07-4226-g003){#F3}

Next, a eukaryotic recombinant EDIL3 protein with high fidelity was generated as previously reported \[[@R15]\] (Figure [4A](#F4){ref-type="fig"}). As EDIL3 was critically involved in vascular morphogenesis and remodeling, we therefore studied the role of EDIL3 in PDAC angiogenesis. Cell-conditioned medium (CM) of EDIL3-higher expression cells (SW1990 and BxPC-3 cells) significantly promoted the human umbilical vein endothelial cells (HUVECs) to develop more capillary-like structures compared with the CM of hTERT-HPNE cells (Figure [4B](#F4){ref-type="fig"}). Similarly, recombinant EDIL3 protein had no obvious implications on cell proliferation, migration, invasion and starvation-induced apoptosis ([Supplementary Figure 2A--2E](#SD1){ref-type="supplementary-material"}), whereas inhibited anoikis (Figure [4C](#F4){ref-type="fig"}, [4D](#F4){ref-type="fig"}) and promoted anchorage-independent tumor growth in a dose-dependent manner (Figure [4E](#F4){ref-type="fig"}). Collectively, these data indicate that EDIL3 promotes anoikis resistance and anchorage-independent growth and this prerequisite facilitates tumor progression.

![EDIL3 stimulation inhibits anoikis and promotes anchorage-independent tumor growth in PDAC cells\
(**A**) Detection of purified recombinant human EDIL3 protein by coomassie blue staining. (**B**) PDAC cells derived EDIL3 promoted tumor angiogenesis *in vitro*. Scale bar: 200 μm. Treatment with recombinant EDIL3 protein inhibited anoikis as revealed by flow cytometry (**C**) and caspase-3/7 activity (**D**), and promoted the colony formation ability (**E**) of PANC1 and AsPC1 cells in a dose-dependent manner. Scale bar: 5 mm. Ctrl versus 10 nM EDIL3 or 100 nM EDIL3, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](oncotarget-07-4226-g004){#F4}

Knockdown of EDIL3 attenuates tumor growth *in vivo* {#s2_5}
----------------------------------------------------

To investigate EDIL3-mediated effects *in vivo*, a subcutaneous xenograft model was used (Figure [5A](#F5){ref-type="fig"}). Indeed, the tumor burden of PDAC in sh-EDIL3 group (sh-1 and sh-2) was significantly reduced compared with the sh-Ctrl group as revealed by tumor volume (Figure [5B](#F5){ref-type="fig"}) and tumor weight (Figure [5C](#F5){ref-type="fig"}). By immunohistochemical analysis, we found that EDIL3 expression in sh-EDIL3 group was markedly reduced compared with the sh-Ctrl group (Figure [5D](#F5){ref-type="fig"}). Furthermore, the decreased expression of PCNA, a marker of cell proliferation, and increased cleaved caspase 3-positive cells were observed in sh-EDIL3 mice compared with those from sh-Ctrl mice (Figure [5E](#F5){ref-type="fig"}, [5F](#F5){ref-type="fig"}). Taken together, our data, as a proof of principle, demonstrate the promotive effect of EDIL3 on tumor growth in PDAC.

![Knockdown of EDIL3 attenuates tumor growth *in vivo*\
(**A**) Three weeks later, mice in sh-EDIL3 group showed relatively larger tumors compared with that in control group. (**B**) Tumor volume in sh-EDIL3 group was smaller than that control group (*n* = 7). (**C**) Tumor weight in sh-EDIL3 group was reduced compared with control group (*n* = 7). (**D**) Representative images of EDIL3, PCNA and cleaved caspase 3 in tissues from sh-EDIL3 and sh-Ctrl mice. Compared with sh-Ctrl mice, decreased expression of PCNA (**E**) and increased expression of cleaved caspase 3 (**F**) was observed in the tissue samples of sh-EDIL3 mice. Scale bar: 100 μm. sh-Ctrl versus sh-1 or sh-2, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](oncotarget-07-4226-g005){#F5}

EDIL3 correlates with altered expression of Bcl-2 family proteins {#s2_6}
-----------------------------------------------------------------

To determine the molecular mechanism underlying EDIL3-mediated anchorage-independent growth of PDAC cells, we detected the effect of EDIL3 on the expression of Bcl-2 family proteins, including Bcl-2, Bcl-xL and Bax, which have been demonstrated to be important for tumor growth and anoikis resistance \[[@R22], [@R23]\]. As shown in Figure [6A](#F6){ref-type="fig"}, knockdown of EDIL3 reduced the protein level of Bcl-2 and Bcl-xL. Upon treatment with recombinant EDIL3 protein, Bcl-2 and Bcl-xL were significantly increased (Figure [6B](#F6){ref-type="fig"}). The pro-apoptotic protein, Bax, was faintly influenced by knockdown or introduction of EDIL3. To further confirm this result, we determined the correlation between EDIL3 and Bcl-2 expression by immunohistochemical analysis. As shown in Figure [6C](#F6){ref-type="fig"}--[6D](#F6){ref-type="fig"}, EDIL3 protein levels in PDAC tissues were positively correlated with the expression levels of Bcl-2 (*r* = 0.399, *p* \< 0.001). Treatment with a specific inhibitor of Bcl-2, ABT-199 (also known as Venetoclax) at 1 μM, EDIL3-mediated anoikis resistance (Figure [6E](#F6){ref-type="fig"}) and anchorage-independent tumor growth (Figure [6F](#F6){ref-type="fig"}) were completely blocked. Taken together, this result indicates that altered expression of Bcl-2 proteins might involve in the oncogenic activities of EDIL3 in PDAC cells.

![EDIL3 correlates with altered expression of Bcl-2 family proteins\
Altered protein expression level of Bcl-2, Bcl-xL and Bax was detected upon knockdown of EDIL3 (**A**) or treatment with recombinant EDIL3 protein (**B**) (**C**) IHC analysis showed representative positive (up) and negative (down) staining of EDIL3 and Bcl-2 in consecutive sections. Indicated areas were marked by a square. Scale bar: 100 μm. (**D**) Statistical analysis of the correlation between EDIL3 and Bcl-2 expression in TMA1. *P* values were calculated by the Spearman rank correlation test. In the presence of 1 μM ABT-199, the effects of recombinant EDIL3 protein (100 nM) on caspase-3/7 activity (**E**) and colony formation ability (**F**) was measured.](oncotarget-07-4226-g006){#F6}

DISCUSSION {#s3}
==========

The current study focused on EDIL3, a well studied cellular protein whose clinical significance and underlying biological functions in PDAC remains unknown. We observed that EDIL3 was commonly up-regulated in both PDAC cell lines and clinical specimens compared with the normal controls. By silencing of EDIL3 expression and treatment with recombinant EDIL3 protein, we demonstrated that EDIL3 conferred PDAC cells with advantages of anoikis resistance and anchorage-independent growth through altering expression of Bcl-2 proteins. Our present findings indicate that EDIL3-related pathway plays an important role in progression of human pancreatic cancer.

In human tissues, EDIL3 expression was identified restricted to endothelial cell in embryo but not adult \[[@R7]\]. Through binding to α~v~β~3~ integrin, EDIL3 regulates endothelial cell attachment and migration as well as inflammatory cell recruitment and engulfment of apoptotic cell \[[@R24]--[@R26]\]. Consistent with the findings in hepatocellular carcinoma, EDIL3 expression was up-regulated during malignant transformation in PDAC \[[@R14], [@R15]\]. In current study, however, EDIL3 expression was also observed in normal pancreas. This may explained by that these normal pancreas tissues were mainly non-tumor tissues derived from patients with PDAC and the tumor microenvironment of PDAC was likely to turn on the expression of EDIL3 in adjacent normal tissues. Previous reports have demonstrated that EDIL3 expression was induced by tumor-derived factors VEGF and p53 could regulate its transcription in primary endothelial cells \[[@R27], [@R28]\]. And recently it has also been reported that EDIL3 was regulated by miR-137 in hepatocellular carcinoma \[[@R16]\]. Despite the critical roles of VEGF and the frequently mutation of p53 in pancreatic cancer, whether this type of modulation contributes to elevated EDIL3 expression remains further investigation \[[@R29]--[@R33]\]. Meanwhile, EDIL3 immunoreactivity was exclusively distributed in tumor cells, but not any positive staining in other cells except islet cells, such as immune cell and stromal cell, suggesting that EDIL3 might constitute an autocrine network in regulating tumor progression in PDAC and indicating that elevated EDIL3 expression might associate with prognosis of PDAC patients. Inconsistent with our findings, Bijlsma et al. have reported the immunoreactivity of EDIL3 in the stroma of pancreatic cancer \[[@R34]\]. However, the representative figures of EDIL3 staining in their paper also showed intense immunoreactivity of EDIL3 in the PDAC cells. This discrepancy may be due to the different clinical specimens analyzed or the different EDIL3 antibodies used.

To address the prognostic value of EDIL3 in PDAC, we performed Kaplan-Meier survival analyses and found that elevated expression of EDIL3 protein was inversely associated with clinical outcomes of PDAC patients. Meanwhile, the univariate and multivariate Cox regression analyses indicated that the up-regulated EDIL3 expression might be a risk factor for the overall survival of PDAC patients. This observation was consistent with the previous finding in hepatocellular carcinoma that elevated EDIL3 was an indicator for the poor prognosis \[[@R14], [@R15]\].

It has been demonstrated that EDIL3 can accelerate tumor growth by enhancing vascular formation and inhibiting tumor cell apoptosis in osteosarcoma and Lewis lung carcinoma \[[@R10]\]. Inconsistent with this, our data revealed that EDIL3 did not show significant implications on anchorage-dependent growth of pancreatic cancer cells. And in line with our previous observations in hepatocellular carcinoma \[[@R15]\], EDIL3 promoted anoikis resistance and anchorage-independent growth of pancreatic cancer cells. This type of difference may be induced by different mechanisms involved in EDIL3-mediated cellular functions in specific tumors. In hepatocellular carcinoma, EDIL3 exhibits its roles through activation of FAK-Src-Akt signaling by interacting with α~v~β~3~ integrin. Apart from triggering an integrin-mediated phosphorylation of FAK-Src, Shc and MAPK, EDIL3 also acts as a survival factor via α~v~β~3~ integrin in endothelial cell \[[@R35]\]. Through inducing expression of the anti-apoptotic protein, Bcl-2, activation of α~v~β~3~ opposes apoptosis of endothelial cell \[[@R21]\]. Consistent with this, treatment with recombinant EDIL3 protein markedly promoted the level of anti-apoptotic protein Bcl-2 and Bcl-xL, and inhibitor of Bcl-2 can completely abolish EDIL3-mediated oncogenic functions. Therefore, the mechanism by which EDIL3 promotes anoikis resistance and anchorage-independent growth may be due, in part, to the alternation of Bcl-2 family protein, which would protect the detached PDAC cells from anoikis.

In conclusion, we describe EDIL3 as a crucial factor in the control of anoikis resistance, anchorage-independent growth and clinical outcomes during human PDAC. Furthermore, we find that EDIL3 exerts its anti-apoptotic function by altering the protein expression of Bcl-2 family. This newly identified EDIL3/Bcl-2 axis might provide a further insight into the pathogenesis of pancreatic cancer and indicate a novel approaches that can be used for the treatment of pancreatic cancer.

MATERIALS AND METHODS {#s4}
=====================

Clinical samples {#s4_1}
----------------

Human pancreatic cancer tissue microarrays (TMA1, OD-CT-DgPan01-006) containing 81 cases of pancreatic ductal adenocarcinoma (PDAC), 44 cases of normal pancreas tissues and 32 cases of chronic pancreatitis tissues were purchased from Shanghai Outdo Biotech Inc. A total of 32 freshly frozen PDAC tissues and corresponding non-cancerous tissues were obtained from Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University between January 2012 and December 2013. TMA2 containing 205 pancreatic cancer specimens and corresponding non-cancerous tissues were also obtained from Ren Ji Hospital from January 2002 to June 2013. The histology and clinical stages were classified according to the seventh edition of the American Joint Committee on Cancer (AJCC) staging system. None of the patients had received radiotherapy, chemotherapy, hormone therapy or other related anti-tumor therapies before surgery. All the patients were provided with written informed consent before enrollment, and the study was approved by the Research Ethics Committee of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University.

Cell culture and reagent {#s4_2}
------------------------

Human PDAC cell lines AsPC1, BxPC-3, CFPAC-1, HPAC, PANC1 and SW1990 were all preserved in Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University and normal human pancreatic ductal cell line hTERT-HPNE was purchased from American Type Culture Collection (ATCC, Manassas, VA). All of these cells were cultured in indicated medium according to ATCC protocols, and supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% antibiotics (100 μg/ml streptomycin and 100 units/ml penicillin) at 37°C in a humidified incubator under 5% CO~2~ condition. Human umbilical vein endothelial cells (HUVECs) were a generous gift from Dr. Huan Yi (Shanghai No.5 People\'s Hospital, Fudan University). ABT-199 was purchased from Selleck (Shanghai, China).

Immunohistochemical staining {#s4_3}
----------------------------

Immunohistochemical (IHC) staining was performed as previously described \[[@R36]\]. Briefly, after tissue sections were deparaffinized, rehydrated with graded ethanol, incubated with 0.3% hydrogen peroxide for 30 minutes and blocked with 10% BSA (Sangon, Shanghai, China), slides were first incubated using the antibody for EDIL3 (dilution 1:200, Proteintech, US), PCNA (dilution 1:5000, CST, US), cleaved caspase 3 (dilution 1:2000, CST, US) and Bcl-2 (dilution 1:300, Proteintech, US) at 4°C overnight, labeled by HRP (rabbit) second antibody (Thermo Scientific, US) at room temperature for 1 h. Finally, positive staining was visualized with DAB substrate liquid (Gene Tech, Shanghai), and counterstained by hematoxylin. All the sections were observed and photographed with a microscope (Carl Zeiss, Germany). Scoring was conducted according to the ratio of positive-staining cells: 0--5% scored 0; 6--35% scored 1; 36--70% scored 2; more than 70% scored 3 and staining intensity: no staining scored 0, weakly staining scored 1, moderately staining scored 2 and strongly staining scored 3. The final score was designated using the percent of positive cell score × staining intensity score as follows: "--" for a score of 0--1, "+" for a score of 2--3, "+ +" for a score of 4--6 and "+ + +" for a score of \> 6; low expression was defined as a total score \< 4 and high expression with a total score ≥ 4. These scores were determined independently by two senior pathologists in a blinded manner.

Quantitative real-time PCR {#s4_4}
--------------------------

Total RNA was extracted from primary tumor and corresponding non-cancerous using Trizol reagent (Takara, Japan), and reversely transcribed through PrimeScript RT-PCR kit (Takara, Japan) according to the manufacturer\'s instructions. Quantitative real-time PCR was performed with SYBR Premix Ex Taq (Takara, Japan) on a 7500 Real-time PCR system (Applied Biosystems, Inc. USA). Primer sequences used in this study were as follows: EDIL3, forward 5′-AGCATACCGAG GGGATACATT-3′, reverse 5′-CAAGGCTCAACTTCGC ATTCA-3′; β-actin, forward 5′-ACTCGTCATACTCC TGCT-3′, reverse 5′-GAAACTACCTTCAACTCC-3′. The 2^−ΔCt^ method was used to quantify the relative EDIL3 expression levels and normalized using the β-actin expression.

Establishment of stable EDIL3 knockdown cell lines {#s4_5}
--------------------------------------------------

Short hairpin RNA (shRNA)-containing plasmids were packaged into lenti-virus and virus titers were determined. Two target cell lines, SW1990 and BxPC-3, were infected with 1 × 10^6^ recombinant lentivirus-transducing units in the presence of 6 μg/ml polybrene (Sigma, Shanghai, China). The sequences targeting EDIL3 are as follows; sh-1: 5′-CCGGGGAGGTTGCATCAGATGAAGACTCGAGTCTTCATCTGATGCAACCTCCTTTTTG-3′; sh-2: 5′- CCGGGGGTATGAAATCAGGACATATCTCGAGATATGTCCTGATTTCATACCCTTTTTG-3′. The stable EDIL3 knockdown cells were selected in the presence of 2 μg/ml puromycin. The knockdown efficacy was tested by western blotting.

Western blotting {#s4_6}
----------------

Cell total protein was extracted using a total protein extraction buffer (Beyotime, China) and the protein concentration was measured using a BCA Protein Assay Kit (Pierce Biotechnology). Cell lysates were separated by 8--12% SDS-PAGE gel electrophoresis and transferred to a PVDF membrane. After blocking with 1% BSA, the membrane was probed with one of the following primary antibodies: EDIL3, Bcl-2, Bcl-xL, Bax, β-actin (Proteintech, US) and species-specific secondary antibodies. Bound secondary antibodies were detected by Odyssey imaging system (LI-COR Biosciences, Lincoln, NE).

Cell viability assay {#s4_7}
--------------------

Recombinant EDIL3 expression, purification and characterization were performed as previously described \[[@R15]\]. For cell viability assay, cells were seeded into a 96-well plate at 3 × 10^3^ cells per well with 100 μl culture medium and cultured at 37°C. The cell viability was quantified by Cell Counting Kit-8 (CCK-8, Dojindo, Japan). Briefly, by addition of 10% (v/v) CCK-8 to the culture medium and incubation for 1 h, cell viability was monitored by measuring absorbance at 450nm using a Power Wave XS microplate reader (BIO-TEK). The experiment was performed in quintuplicate and repeated twice.

Cell migration and invasion assay {#s4_8}
---------------------------------

The invasive potential of PDAC cells was measured by transwell model (Corning, NY, USA) according to the manufacturer\'s instructions. For migration assay, 2 × 10^4^ cells in 100 μl medium were seeded into the upper chamber of the transwell inserts. The invasion assay was performed with matrigel-coated filters (BD Bioscience, USA). RPMI 1640 or DMEM medium containing 5 % (v/v) FBS and recombinant EDIL3 was added to the bottom chamber. Cells were incubated at 37°C and allowed to migrate for 24 h or invade through Matrigel for 48 h. At the designated time points, the non-invading cells that remained on the upper surface were removed. The migrated and invaded cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of cells on the lower surface was counted under a light microscope in six random fields. Each experiment was performed in triplicate and repeated twice.

Apoptosis and anoikis assay {#s4_9}
---------------------------

For cell apoptosis assay, 20 × 10^5^ cells per well in the presence or absence of recombinant EDIL3 treatment were cultured under serum-deprivation in 6-well plates. Adherent cells were detached with 0.25% trypsin without EDTA in 1 × PBS. Cells were harvested in complete RPMI 1640 or DMEM medium and centrifuged at 1000 rpm for 5 min. Each of the cells were washed with 1 × PBS, stained with 50 μg/ml propidium iodide (PI) and Annexin V-FITC (BD Pharmingen, USA) following the manufacturer\'s instructions. The percentage of Annexin V (+) and PI (−) cells were analyzed by flow cytometry. For anoikis assay, Annexin V/PI staining and Caspase-3/7 activity (Promega, USA) were performed as previously described \[[@R15]\].

Colony formation assay {#s4_10}
----------------------

Colony formation in soft agar was performed to evaluate anchorage-independent growth. A total of 1.0 ml of RPMI 1640 or DMEM medium containing 10% FBS and 0.5% agar was plated in the bottom of 6-well plates. PANC1 or AsPC1 cells at 2 × 10^3^ cells per well were suspended in the upper layer consisted of 1% FBS culture medium and 0.35% agar. For knockdown assay, cells were fed every 2 days with complete medium. For EDIL3 stimulation assay, the soft agars were fed every 2 days with serum-free culture medium in the presence or absence of recombinant EDIL3 at indicated concentrations. After 14--21 days, colonies were stained with 0.05% crystal violet, and all the visible colonies were counted by microscopy.

Animal experiments {#s4_11}
------------------

Mice were manipulated and housed according to protocols approved by the East China Normal University Animal Care Commission. All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health. Athymic male NU/NU mice ages 6 weeks were kept on a 12-hour day/night cycle with free access to food and water. SW1990 cells were trypsinized (Invitrogen, USA), washed in PBS, and resuspended in serum-free DMEM. A total of 3 × 10^6^ SW1990 cells in 200 ul DMEM medium were injected subcutaneously in the lower back. Tumor growth was monitored after three weeks after mouse were sacrificed.

Statistical analysis {#s4_12}
--------------------

Data were presented as the means ± SD. The SPSS software program (version 17.0; IBM Corporation) was used for statistical analysis. Graphical representations were performed with GraphPad Prism 5 (San Diego, CA) software. Correlation of EDIL3 expression with clinicopathologic parameters in patients with PDAC was evaluated by chi-square test or Fisher\'s exact test. Survival curves were evaluated using the Kaplan-Meier method and differences between survival curves were tested by the log-rank test. Univariate and multivariate Cox regression analyses were performed to identify the factors that had a significant influence on survival by Cox proportional hazards model. The student\'s *t*-test or one-way ANOVA was used for comparison between groups. *P* \< 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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